Genervon
 | This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages)
|
Genervon Biopharmaceuticals is a pharmaceutical company based in Pasadena, CA, focused on creating drugs for diseases of the central human nervous system.[1] It is best known for its experimental drug, GM604, which seeks to treat Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease.
GM604[edit]
GM604 is the temporary name of a drug under development by Genervon that is supposed to slow the progression of ALS. The drug is currently in the Phase II approval process of the FDA after a 12-week clinical trial was performed on 12 patients. Genervon has claimed that the trial revealed that treatment with GM604 resulted in a statistically significant and robust slow down in the progression of the disease. The results of this trial encouraged ALS support groups and patients to petition Congress and the FDA to speed up approval of the drug, with a petition on Change.org receiving nearly 800,000 signatures.[2]
Despite Genervon's claims, experts in the industry such as Steve Perrin, the chief executive officer of the ALS Therapy Development Institute, and John Carroll of Fiercebiotech.com have challenged the significance of the trial, specifically objecting to the small number of patients in the early-phase trial, and cautioned that an accelerated approval process seems premature.[3][4][5]
On May 30, 2016, European Commission approved and implemented the decision relating to the designation of "GM604" as an orphan medicinal product under Regulation (EC) No 141/2000 of the European Parliament and of the Council.[6]
Current drug development[edit]
While Genervon has not yet released any drugs for the market, it is in the process of developing three drugs for which it has submitted Investigational New Drug applications which are in Phase II trials. These drugs seek to treat acute ischemic stroke patients under (IND #77789), Parkinson's disease (IND #10944) and ALS (GM604, IND #118420).[7]
External links[edit]
References[edit]
- ^ "About Genervon". Genervon. Retrieved 14 January 2016.
- ^ Silverman, Ed (20 April 2015). "A Dispute Flares Over Data for a Nascent ALS Drug and an FDA Review". The Wall Street Journal. Retrieved 14 January 2016.
- ^ Perrin, Steve. "GM604: Is it Ready For FDA Approval?". Retrieved 14 January 2016.
- ^ "What's driving the massive social media campaign for Genervon's ALS drug?". Fierce Biotech. 20 April 2015. Retrieved 14 January 2016.
- ^ Carroll, John (21 April 2015). "Shifting positions, Genervon now admits it has yet to file for ALS drug OK". Fierce Biotech. Retrieved 14 January 2016.
- ^ "Genervon". Archived from the original on 2016-11-18. Retrieved 2016-11-17.
- ^ "Medicines". Genervon. Retrieved 14 January 2016.